Assessment of the cognitive function in adult Egyptian patients with obstructive sleep apnea using the Montreal Cognitive Assessment: a retrospective large-scale study.

STUDY OBJECTIVES: Sleep apnea is a chronic disorder associated with multiple recognized comorbidities. Only a few studies focus on evaluating the cognitive profile in patients diagnosed with sleep apnea. The aim of the study was to assess the cognitive functions in this population using the Montreal Cognitive Assessment. METHODS: The study cohort was 1,445 adult patients who were referred for overnight polysomnography, 764 cases and 681 healthy controls. All participants' clinical data and comorbidities were taken, and they all performed overnight polysomnography and Montreal Cognitive Assessment. RESULTS: A significantly higher proportion (57.5%) of sleep apnea groups were males; 15.7% were illiterate compared to the non-sleep apnea group. Hypertension and diabetes mellitus were significantly more prevalent among studied patients with sleep apnea, and the mean total score for the Montreal Cognitive Assessment scale was significantly lower among those with sleep apnea at P < .001. Those with no sleep apnea showed a significantly higher function in all attributes compared to patients with sleep apnea-namely, language, orientation, abstraction, naming, attention, and recall (P < .05). CONCLUSIONS: Logistic regression analysis was conducted to investigate predictors for occurrence of cognitive impairment (Montreal Cognitive Assessment score < 26) among the studied sample (n = 1,445). The overall model was significant at P < .001. Variables that showed significance in univariate analysis were entered in the model. Significant predictors for cognitive impairment were being male, older age, diabetic, hypertensive, and with a lower level of education and having sleep apnea. CITATION: Mekky JF, Yousof S, Elsayed I, Elsemelawy R, Mahmoud H, Elweshahi H. Assessment of the cognitive functions in adult Egyptian patients with obstructive sleep apnea using the Montreal Cognitive Assessment: a retrospective large-scale study. J Clin Sleep Med. 2022;18(3):721-729.

Rapid eye movement (REM) sleep and seizure control in idiopathic generalized epilepsy.

BACKGROUND: Sleep and epilepsy are bedfellows, and they affect each other reciprocally. Despite the well-known relationship between sleep and epilepsy, data about the impact of sleep on seizure control and responsiveness to therapy are scarce. OBJECTIVE: The aim of this work was to study the impact of sleep architecture in drug-naïve patients with idiopathic generalized epilepsy (IGE) on seizure control and responsiveness to treatment. METHODS: This is a prospective cohort study conducted on thirty newly diagnosed patients with IGE attending the epilepsy clinic in Alexandria University Hospital in Egypt and thirty healthy controls. All recruited subjects had a baseline overnight polysomnographic study, then patients were given sodium valproate in therapeutic doses and followed up for six months for assessment of seizure control. After follow-up, they were classified into fully controlled and inadequately controlled patients, and a comparison between them was made. RESULTS: Of the recruited patients, 13 were fully controlled. Rapid eye movement (REM) sleep % was significantly lower among inadequately controlled patients (9.01 ±â€¯6.23) than fully controlled group (19.6 ±â€¯9.01) and controls (18.17 ±â€¯4.85) (p = 0.002), and the REM sleep latency was significantly longer among the inadequately controlled patients (115.7 ±â€¯72.8 min) than fully controlled patients (54.6 ±â€¯77.3 min) and controls (68.75 ±â€¯37.95 min) (p = 011). On univariate regression analysis, the Odd's ratio (OR) for REM sleep percentage was 3.04 (p = 0.001). CONCLUSION: Rapid eye movement sleep percentage and latency can contribute to seizure control in IGE.

Correlation of levetiracetam concentration in peripheral blood mononuclear cells with clinical efficacy: A sensitive monitoring biomarker in patients with epilepsy.

PURPOSE: Therapeutic drug monitoring (TDM) is increasingly recommended in antiepileptic drug (AED) therapy, yet a complex relationship exists between the unbound-drug serum concentration (Cu.serum) as a monitoring biomarker and clinical efficacy. The study was designed to investigate the validity of the intracellular unbound-drug concentration in Peripheral Blood Mononuclear Cells (Cu.PBMC) as a feasible TDM tool in relation to levetiracetam (LEV). METHODS: Patients from epilepsy out-patient centre were included in a 4-month descriptive prospective study. Trough serum and PBMC LEV concentrations were monthly determined using HPLC and correlated with clinical features, demographic data, and P-glycoprotein (P-gp) expression. RESULTS: Seventy-patients completed the study with a LEV dose range of 500-3000 mg/day. An absolute range for LEV Cu.serum and Cu.PBMC was 1.00-26.99 and 0.33-4.43 µg/mL, respectively. Unlike Cu.serum, the average four-month LEV Cu.PBMC displayed a significant positive correlation with clinical features and P-gp expression; where patients with higher LEV Cu.PBMC experienced less number of seizure/month, better cognition and quality of life, and had a more reduction in P-gp expression, but no significant correlation with LEV daily dose was observed. A therapeutic response threshold of ≥ 0.82 µg/mL for LEV Cu.PBMCwas perceived by using a receiver operating characteristic curve that related the number of seizure/month to the LEV Cu.PBMC. The validity of this therapeutic threshold was significant in contrast to LEV Cu.serum. CONCLUSION: Levetiracetam PBMC concentration is a more sensitive biomarker for LEV efficacy and correlates better with clinical events than Cu.serum and could represent a novel tool for more precise LEV monitoring.

Sleep architecture in patients with Juvenile Myoclonic Epilepsy.

AIM: The aim is to analyze the sleep architecture using polysomnography (PSG) in patients with Juvenile Myoclonic Epilepsy (JME): (newly diagnosed and those on valproate drug) attending epilepsy clinic at Alexandria University Hospitals. METHODS: This study involved 20 patients with JME on valproate (age: 22.40 ± 5.80 years; M:F = 6:14), 20 newly diagnosed patients (age: 18.55 ± 6.0 years; M:F = 6:14), and 20 matched healthy controls (age: 22.10 ± 5.0 years; M:F = 6:14). Clinical assessment, electroencephalogram (EEG), evaluation with comprehensive sleep questionnaire, and PSG were done for all patients. RESULTS: PSG showed significant alterations in sleep architecture in the total JME group in the form of reduced mean sleep efficiency (p = 0.001∗), increased mean Rapid eye movement (REM) onset latency (p = 0.046∗), decrease mean REM percentage (p = 0.011∗), increased mean wakefulness after sleep onset (p = 0.018∗), increase the index of total arousal (p = 0.005∗), increased mean periodic limb movement index (P = 0.001∗), and reduced apnea hypopnea index (P = <0.001) in comparison to control group. Valproate treated group showed increased sleep efficiency (p = 0.040∗), decreased REM arousal index (P = 0.012), longer stage 3 (P = 0.038), and prolonged stage 2 (P = 0.049∗) than the newly diagnosed group. CONCLUSIONS: Sleep architecture was significantly disturbed in JME, with improvement in sleep efficiency in valproate treated patients.